You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on cancer immunotherapy.
The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.
The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies.
The company is hoping that the comprehensive solution will help bring on more pharma customers and offer extended opportunities for current users.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
The company is hoping its technology can help predict which melanoma patients will respond to checkpoint inhibition using immune-related gene expression signals.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
The company is on track to submit Guardant360 to the FDA in the third quarter, but also expects to see pan-cancer reimbursement much sooner.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.